Evidence map›Paper›PMID 33615164›Full record

ArticleACS pharmacology & translational science2021

Cytotoxicity, Retention, and Anti-inflammatory Effects of a CeO

Christoph Eilenberger, Florian Selinger, Mario Rothbauer, Yiji Lin, Andreas Limbeck, Barbara Schädl, Johannes Grillari, Nataliya S Kavok, Vladimir K Klochkov, Yuri V Malyukin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. iScience · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christoph EilenbergerInstitute of Chemical Technologies and Analytics and Institute of Applied Synthetic Chemistry, Faculty of Technical Chemistry, Vienna University of Technology, Getreidemarkt 9, 1060 Vienna, Austria.
Florian SelingerInstitute of Chemical Technologies and Analytics and Institute of Applied Synthetic Chemistry, Faculty of Technical Chemistry, Vienna University of Technology, Getreidemarkt 9, 1060 Vienna, Austria.
Mario RothbauerInstitute of Chemical Technologies and Analytics and Institute of Applied Synthetic Chemistry, Faculty of Technical Chemistry, Vienna University of Technology, Getreidemarkt 9, 1060 Vienna, Austria.
Yiji LinInstitute of Chemical Technologies and Analytics and Institute of Applied Synthetic Chemistry, Faculty of Technical Chemistry, Vienna University of Technology, Getreidemarkt 9, 1060 Vienna, Austria.
Andreas LimbeckInstitute of Chemical Technologies and Analytics and Institute of Applied Synthetic Chemistry, Faculty of Technical Chemistry, Vienna University of Technology, Getreidemarkt 9, 1060 Vienna, Austria.
Barbara SchädlLudwig-Boltzmann-Institute for Experimental and Clinical Traumatology, Donaueschingenstraße 13, 1200 Vienna, Austria.
Johannes GrillariLudwig-Boltzmann-Institute for Experimental and Clinical Traumatology, Donaueschingenstraße 13, 1200 Vienna, Austria.
Nataliya S KavokInstitute for Scintillation Materials, STC "Institute for Single Crystals", 60 Science Avenue, 61001 Kharkiv, Ukraine.
Vladimir K KlochkovInstitute for Scintillation Materials, STC "Institute for Single Crystals", 60 Science Avenue, 61001 Kharkiv, Ukraine.
Yuri V MalyukinInstitute for Scintillation Materials, STC "Institute for Single Crystals", 60 Science Avenue, 61001 Kharkiv, Ukraine.
Victor MargitichFarmak JSC, 63, Kyrylivska Street, Kiev 04080, Ukraine.
Peter ErtlInstitute of Chemical Technologies and Analytics and Institute of Applied Synthetic Chemistry, Faculty of Technical Chemistry, Vienna University of Technology, Getreidemarkt 9, 1060 Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both cerium oxide (CeOx) nanoparticles and mefenamic acid (MFA) are known anti-inflammatory agents with hepatoprotective properties and are therefore prescribed for one of the major diseases in the world, nonalcoholic fatty liver disease (NAFLD). To study the potential cytotoxicity and anti-inflammatory effects as well as drug retention of a potential therapeutic CeOx/MFA supramolecular complex, a well-standardized hepatic (HepG2) spheroid model was used. Results showed that the highest cytotoxicity for the CeOx/MFA supramolecular complex was found at 50 μg/mL, while effective doses of 0.1 and 1 μg/mL yielded a significant decrease of TNF-α and IL-8 secretion. Time-resolved analysis of HepG2 spheroids revealed a spatiotemporal distribution of the supramolecular complex and limited clearance from the internal microtissue over a period of 8 days in cultivation. In summary, our results point at rapid uptake, distribution, and biostability of the supramolecular complex within the HepG2 liver spheroid model as well as a significant anti-inflammatory response at noncytotoxic levels.

Identifiers

PMID33615164
PMCPMC7887746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.